A Study of Four Drugs for Older Adults with DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older and have been diagnosed with DLBCL that has not been treated yet.
- You have at least one tumor that can be seen on imaging and is at least 1.5 cm in size.
- Your heart, liver, kidneys, and lungs are working well enough as determined by certain tests.
- You have adequate blood cell counts (like red blood cells, platelets, and white blood cells).
- You are willing to use birth control if needed, and you can understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three newer targeted drugs for older adults (70+) who have just been diagnosed with diffuse large B-cell lymphoma and have not yet received any treatment. The goal is to see if this drug combo can control the lymphoma effectively while being manageable for older patients.
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.